Dexmedetomidine for Sedation in Total Knee Replacements

Phase 3 Completed 54 enrolled University of Saskatchewan

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Dexmedetomidine has demonstrated benefits both in sedation, and post-operative pain control, with less respiratory depression than other common sedatives. Traditionally, dexmedetomidine has been used with a large loading dose and infusion, which has been known to cause dose-dependent negative side-effects (Abdallah et al., 2013). Single dose dexmedetomidine produces less negative side-effects, but still effective sedation and reduced post-operative pain (Jung et al., 2013). There is evidence for its benefits with general anesthesia but only a few studies exist investigating its benefits when administered for sedation purposes with spinal anesthesia, and no studies primarily examine post-operative opioid consumption. The investigators hypothesize that single dose dexmedetomidine for procedural sedation will reduce opioid consumption after total knee arthroplasty (TKA).

Timeline

Start: 2015-06
Primary completion: 2015-11
Completion: 2015-11

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexmedetomidine	Other / unclassified	0.5 ug/kg	—
Background	Bupivacaine	Other / unclassified	12.75 mg	Other
Background	Fentanyl	Other / unclassified	10 ug	Other
Background	Midazolam	Small molecule	4 mg	Intravenous

Indications

No indication recorded.